EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy

Susanne Halken; Desiree Larenas-Linnemann; Graham Roberts; Moises A Calderón; Elisabeth Angier; Oliver Pfaar; Dermot D Ryan; Ioana Agache; Ignacio J I J Ansotegui; Stefania Arasi; George Du Toit; Montserrat Fernandez-Rivas; Roy Geerth van Wijk; Marek Jutel; Jörg Kleine-Tebbe; Susanne Lau; Paolo M Matricardi; Giovanni B Pajno; Nikolaos G Papadopoulos; Martin Penagos; Alexandra F Santos; Gunter J Sturm; Frans Timmermans; R Van Ree; Eva-Maria Varga; Ulrich Wahn; Maria Kristiansen; Sangeeta Dhami; Aziz Sheikh; Muraro Antonella

doi:10.1111/pai.12807

EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy

Susanne Halken, Desiree Larenas-Linnemann, Graham Roberts, Moises A Calderón, Elisabeth Angier, Oliver Pfaar, Dermot D Ryan, Ioana Agache, Ignacio J I J Ansotegui, Stefania Arasi, George Du Toit, Montserrat Fernandez-Rivas, Roy Geerth van Wijk, Marek Jutel, Jörg Kleine-Tebbe, Susanne Lau, Paolo M Matricardi, Giovanni B Pajno, Nikolaos G Papadopoulos, Martin PenagosAlexandra F Santos, Gunter J Sturm, Frans Timmermans, R Van Ree, Eva-Maria Varga, Ulrich Wahn, Maria Kristiansen, Sangeeta Dhami, Aziz Sheikh, Muraro Antonella

90 Citations (Scopus)

Abstract

Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer-review of draft recommendations. Our key recommendation is that a 3-year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate-to-severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post-AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease-modifying treatment exists but there is an urgent need for more high-quality clinical trials.

Original language	English
Journal	Pediatric Allergy and Immunology
Volume	28
Issue number	8
Pages (from-to)	728-745
Number of pages	18
ISSN	0905-6157
DOIs	https://doi.org/10.1111/pai.12807
Publication status	Published - Dec 2017

Keywords

Journal Article
Review

Access to Document

10.1111/pai.12807

Cite this

Halken, S., Larenas-Linnemann, D., Roberts, G., Calderón, M. A., Angier, E., Pfaar, O., Ryan, D. D., Agache, I., Ansotegui, I. J. I. J., Arasi, S., Du Toit, G., Fernandez-Rivas, M., Geerth van Wijk, R., Jutel, M., Kleine-Tebbe, J., Lau, S., Matricardi, P. M., Pajno, G. B., Papadopoulos, N. G., ... Antonella, M. (2017). EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy. Pediatric Allergy and Immunology, 28(8), 728-745. https://doi.org/10.1111/pai.12807

Halken, S, Larenas-Linnemann, D, Roberts, G, Calderón, MA, Angier, E, Pfaar, O, Ryan, DD, Agache, I, Ansotegui, IJIJ, Arasi, S, Du Toit, G, Fernandez-Rivas, M, Geerth van Wijk, R, Jutel, M, Kleine-Tebbe, J, Lau, S, Matricardi, PM, Pajno, GB, Papadopoulos, NG, Penagos, M, Santos, AF, Sturm, GJ, Timmermans, F, Van Ree, R, Varga, E-M, Wahn, U, Kristiansen, M, Dhami, S, Sheikh, A & Antonella, M 2017, 'EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy', Pediatric Allergy and Immunology, vol. 28, no. 8, pp. 728-745. https://doi.org/10.1111/pai.12807

@article{0e204fe7d67549eb88b09405ee50919e,

title = "EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy",

abstract = "Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer-review of draft recommendations. Our key recommendation is that a 3-year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate-to-severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post-AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease-modifying treatment exists but there is an urgent need for more high-quality clinical trials.",

keywords = "Journal Article, Review",

author = "Susanne Halken and Desiree Larenas-Linnemann and Graham Roberts and Calder{\'o}n, {Moises A} and Elisabeth Angier and Oliver Pfaar and Ryan, {Dermot D} and Ioana Agache and Ansotegui, {Ignacio J I J} and Stefania Arasi and {Du Toit}, George and Montserrat Fernandez-Rivas and {Geerth van Wijk}, Roy and Marek Jutel and J{\"o}rg Kleine-Tebbe and Susanne Lau and Matricardi, {Paolo M} and Pajno, {Giovanni B} and Papadopoulos, {Nikolaos G} and Martin Penagos and Santos, {Alexandra F} and Sturm, {Gunter J} and Frans Timmermans and {Van Ree}, R and Eva-Maria Varga and Ulrich Wahn and Maria Kristiansen and Sangeeta Dhami and Aziz Sheikh and Muraro Antonella",

year = "2017",

month = dec,

doi = "10.1111/pai.12807",

language = "English",

volume = "28",

pages = "728--745",

journal = "Pediatric Allergy and Immunology",

issn = "0905-6157",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - EAACI Guidelines on Allergen Immunotherapy

T2 - Prevention of allergy

AU - Halken, Susanne

AU - Larenas-Linnemann, Desiree

AU - Roberts, Graham

AU - Calderón, Moises A

AU - Angier, Elisabeth

AU - Pfaar, Oliver

AU - Ryan, Dermot D

AU - Agache, Ioana

AU - Ansotegui, Ignacio J I J

AU - Arasi, Stefania

AU - Du Toit, George

AU - Fernandez-Rivas, Montserrat

AU - Geerth van Wijk, Roy

AU - Jutel, Marek

AU - Kleine-Tebbe, Jörg

AU - Lau, Susanne

AU - Matricardi, Paolo M

AU - Pajno, Giovanni B

AU - Papadopoulos, Nikolaos G

AU - Penagos, Martin

AU - Santos, Alexandra F

AU - Sturm, Gunter J

AU - Timmermans, Frans

AU - Van Ree, R

AU - Varga, Eva-Maria

AU - Wahn, Ulrich

AU - Kristiansen, Maria

AU - Dhami, Sangeeta

AU - Sheikh, Aziz

AU - Antonella, Muraro

PY - 2017/12

Y1 - 2017/12

N2 - Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer-review of draft recommendations. Our key recommendation is that a 3-year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate-to-severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post-AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease-modifying treatment exists but there is an urgent need for more high-quality clinical trials.

AB - Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer-review of draft recommendations. Our key recommendation is that a 3-year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate-to-severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post-AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease-modifying treatment exists but there is an urgent need for more high-quality clinical trials.

KW - Journal Article

KW - Review

UR - https://www.ncbi.nlm.nih.gov/pubmed/28902467

U2 - 10.1111/pai.12807

DO - 10.1111/pai.12807

M3 - Review

C2 - 28902467

SN - 0905-6157

VL - 28

SP - 728

EP - 745

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

IS - 8

ER -

EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this